<DOC>
	<DOCNO>NCT01920464</DOCNO>
	<brief_summary>study request french health authority evaluate use flixovate infant place treatment pathway . study 2 main pbjectives : 1/ Evaluation change prescription share Flixovate® compare topical corticosteroid ( low , medium high potency ) population infant age 3 12 month , 1st January 2010 31st December 2012 . 2/Description condition use Flixovate® infant age less 12 month ( infant profile , dosage form , dosage , treatment duration , prior , concomitant subsequent treatment etc . ) .</brief_summary>
	<brief_title>Place Flixovate® Treatment Pathway Its Conditions Use Infants Aged From 3 12 Months Between 2010 2012 French GPs Private Paediatricians</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Analysis change share prescription : Infants receive least one prescription topical steroid 1st January 2010 31st December 2012 . Infants age 3 12 month day prescription topical steroid . Description condition use patient profile : Infants receive least one prescription topical steroid 1st January 2010 31st December 2012 . Infants age 3 12 month day prescription topical steroid .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>